An interventional study of Multimodal Exercise and Cognitve and Social Activities in Stroke and Poor Quality Sleep, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by University of British Columbia · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Stroke by University of British Columbia — 3 open to participants now, 4 under way, none of them phase 3. Stroke · University of British Columbia.
Among the 30 studies in Stroke by University of British Columbia, this one is the 13th largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2025, is one of 24 with no phase, and was the 29th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →3 of the 30 studies in Stroke by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:
University of British Columbia · Sites in Canada
Ages 19+
University of British Columbia · Sites in Canada
Ages 18+
By country, each count listing its studies:
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 62 is above the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 62 across the 25 interventional studies, 60 across the 5 observational. Of the 19 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of British Columbia is the lead sponsor of 1,342 studies on the registry; 262 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
1 of the studies in Stroke by University of British Columbia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05724823University of British ColumbiaVirtual Physical Activity Seated Exercise - Phase 2 | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Stroke by University of British Columbia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
health problems, such as heart disease, diabetes, cognitive impairment, and dementia.
After a person suffers a stroke, they often experience difficulties in getting a good night's sleep. Approximately half of stroke survivors have insomnia, or have trouble falling and/or staying asleep. Poor sleep quality among stroke survivors increases the risk of recurrent stroke by 3-fold and the risk of early death by 76%. Hence, stroke survivors need strategies to promote better sleep.
Fortunately, evidence shows that sleep quality can be improved with exercise, even among those who struggle with insomnia. Whether exercise training can improve sleep quality in adults with chronic stroke (i.e., at least 12 months has passed since their stroke) and poor sleep quality is not known. In addition, it is unknown if improved sleep is associated with improved outcomes in those with chronic stroke.
This study will specifically evaluate the effect of twice-weekly targeted exercise training on sleep quality over a 6-month period in persons with chronic stroke and poor sleep quality. This study will also evaluate the effect of exercise on the following outcomes: 1) sleep structure; 2) fatigue; 3) daytime sleepiness; 4) mood; 5) physical function and capacity; 6) thinking abilities; 7) heart health; and 8) quality of life. Finally, this study will examine how changes in sleep quality may be related to changes in these outcomes. Our proposed research is timely as the importance of sleep to recovery, health, and wellbeing post-stroke is increasingly recognized.
Approximately half of stroke survivors have insomnia. Poor sleep quality among stroke survivors increases the risk of recurrent stroke by 3-fold and the risk of early death by 76%. Hence, stroke survivors are a target population in need of intervention strategies to promote sleep quality.
Current research and stroke rehabilitation do not address the sleep consequences of stroke - especially for those in the chronic phase (i.e., = or > 12 months since an index stroke). Adults with chronic stroke have lower sleep efficiency compared with sex- and age-matched controls. Poor sleep quality in chronic stroke is associated with depression, impaired physical function, and reduced cognitive function.
How to effectively treat insomnia in adults with chronic stroke is not well established. Intervention studies show exercise improves sleep quality and structure. Whether exercise can improve sleep quality in adults with chronic stroke and poor sleep quality is not established.
Primary Question: In adults with chronic stroke and poor sleep quality, can a 26-week multimodal exercise training program of moderate intensity (EX) improve sleep efficiency, as objectively measured by the actigraphy, compared with a 26-week cognitive and social activities program (CON; active control group)?
Secondary Question: What are additional benefits of EX vs. CON? Compared with CON, we will evaluate the effect of EX on: 1) actigraphy-measured sleep parameters of latency, duration, and wake after sleep onset; 2) sleep architecture by frontal electroencephalography; 3) subjective sleep quality; 4) fatigue; 5) daytime sleepiness; 6) mood; 7) functional capacity; 8) cognitive function; 9) cardiometabolic risk factors; and 10) quality of life.
Tertiary Question: Are changes in sleep quality associated with changes in: 1) fatigue; 2) daytime sleepiness; 3) mood; 4) cognitive function; 5) cardiometabolic risk factors; and 6) quality of life?
Pilot Data: Using actigraphy, the investigators acquired sleep data from 21 of 120 (i.e., subset) participants with chronic stroke enrolled in a RCT with cognitive function as the primary outcome. These 21 participants (mean age=69) were randomized to 26 weeks of: 1) multimodal exercise of moderate intensity (EX; n=12); or 2) cognitive and social activities (i.e., no exercise; CON; n=9). Of these 21 participants, 48% had a baseline actigraphy-measured sleep efficiency \< 85%. Compared with CON, EX significantly improved actigraphy-measured sleep efficiency values (in %) at 13 weeks and 26 weeks.
Methods: A 26-week, assessor-blinded, single-site RCT of 62 community-dwelling adults with chronic stroke, WatchPAT measured sleep efficiency \< 85%, Pittsburgh Sleep Quality Index global score > 5, and aged 55 years and older. Individuals will be randomized to one of two experimental groups: 1) twice-weekly EX (n=31); or 2) twice-weekly CON (n=31). Randomization will be stratified by sex and age. Measurement will occur at baseline, 13 weeks, and 26 weeks, unless otherwise stated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
We will include community-dwelling adults who had an ischemic or hemorrhagic stroke at least one year prior to study enrolment and have poor sleep quality - defined as a sleep efficiency of \< or = 85%, with allowance for minor upward deviations on individual nights consistent with known night-to-night variability and instrument accuracy limits, and a PSQI global score of > 5. Individuals must also meet these inclusion criteria: 1) aged 55 years and older; 2) a baseline score of = or > 22/30 and a MoCA score of = or > 19/30; 3) community-dwelling; 4) able to comply with scheduled assessments, classes, and other trial procedures; 5) read, write, and speak English with acceptable visual and auditory acuity; 6) not to start or stable (i.e., = or > 6 months) on a fixed dose of medication that impacts sleep (i.e., anti-arrhythmics, beta blockers, selective serotonin reuptake inhibitor, etc.) during the 26-week intervention period; 7) able to walk for a minimum of six metres with rest intervals with or without assistive devices; 8) based on interview, have an activity tolerance of 60 minutes with rest intervals; 9) not participating in any regular therapy or progressive exercise (e.g., treadmill or weight-lifting); and 10) able to safely engage in exercise as indicated by the PAR-Q+63 and written confirmation by family or study physicians.
Exclusion Criteria:
We will exclude individuals who: 1) are diagnosed with OSA and are not using CPAP or defined as potentially having undiagnosed OSA (AHI > 20) as a result of study screening; 2) have restless leg syndrome; 3) are diagnosed with dementia of any type; 4) are diagnosed with another type of neurodegenerative or neurological condition (e.g., Parkinson's disease); 5) are planning to participate, or already enrolled in, a clinical drug trial or exercise trial concurrent to this study; 6) are at high risk for cardiac complications during exercise and/or unable to self-regulate activity or to understand recommended activity level; 7) have peripheral neuropathy or severe musculoskeletal or joint disease that impairs mobility, as determined by his/her physician; or 8) have aphasia as judged by an inability to communicate by phone.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The program will consist of moderate intensity, multimodal exercise training; 2x/week; in-person, group-based.
Behavioral: Multimodal Exercise
The program will consist of cognitive and social activites; 2x/week; in-person, group-based
Behavioral: Cognitve and Social Activities
Each 60-minute class will include a 10-minute warm-up (i.e., stretches for the major muscles and walking on the spot), 40 minutes of training, and a 10-minute cool down (i.e., stretches and relaxation techniques).Instructors will use heart rate monitors to continuously track intensity during and across all sessions.
Each 60-minute class will include 30 minutes of cognitive enrichment activities and 30 minutes of activities that promote social interactions.
Sleep Efficiency
Sleep efficiency as measured by actigraphy over days of wear.
Time frame: Baseline, 13 weeks, 26 weeks
Sleep latency, duration, and wake after sleep onset
Sleep latency, duration, and wake after sleep onset by actigraphy over days of wear.
Time frame: Baseline, 13 weeks, 26 weeks
Sleep Architecture (OPTIONAL)
Sleep architecture as measured by EEG headband
Time frame: Baseline, 13 weeks, 26 weeks
Subjective sleep quality
Subjective sleep quality measured by Pittsburgh Sleep Quality Index
Time frame: Baseline, 13 weeks, 26 weeks
Fatigue
Fatigue measured by Fatigue Severity Scale
Time frame: Baseline, 13 weeks, 26 weeks
Sleepiness
Daytime sleepiness measured by questionnaire
Time frame: Baseline, 13 weeks, 26 weeks
Mood
Depressive symptoms measured by questionnaire
Time frame: Baseline, 13 weeks, 26 weeks
Functional Capacity
Functional capacity, or aerobic capacity, measured by the 6-Minute Walk Test
Time frame: Baseline, 13 weeks, 26 weeks
NIH Toolbox Cognitive Battery
Cognitive function measured by NIH Toolbox Cognitive Battery
Time frame: Baseline, 13 weeks, 26 weeks
ADAS-Cog Plus
Cognitive function measured by ADAS-Cog Plus
Time frame: Baseline, 13 weeks, 26 weeks
Executive Functions
The domain of executive functions measured by Trails A and B, Digits Forward and Backward, and Clock Drawing
Time frame: Baseline, 13 weeks, 26 weeks
Verbal Fluency
Verbal fluency measured by categorical fluency
Time frame: Baseline, 13 weeks, 26 weeks
Memory
Memory measured by the Rey Auditory Verbal Fluency
Time frame: Baseline, 13 weeks, 26 weeks
Blood Pressure
Systolic and diastolic blood pressure
Time frame: Baseline, 13 weeks, 26 weeks
Chronotype
Chronotype measured by questionnaire
Time frame: Baseline, 13 weeks, 26 weeks
Blood Biomarkers (OPTIONAL)
We will draw blood to assess markers cardiometabolic health and brain health
Time frame: Baseline, 13 weeks, 26 weeks
Quality of life
Quality of life measured by the EuroQol-5 Domain-5 Level (EQ-5D-5L)
Time frame: Baseline, 13 weeks, 26 weeks
Current Physical Activity (Self-Report)
Physical activity outside of research study will be assessed by questionnaire
Time frame: Baseline, 13 weeks, 26 weeks
Balance and Mobility
Balance and mobility measured by the Short Physical Performance Battery
Time frame: Baseline, 13 weeks, 26 weeks
Activities of Daily Living
Lawton and Brody Instrumental Activities of Daily Living Scale will asssess activites of daily living
Time frame: Baseline, 26 weeks
Arterial Stiffness
Arterial stiffness will be measured as pulse wave velocity
Time frame: Baseline, 13 weeks, 26 weeks
Sedentary Behaviour
Time in sedentary behaviour will be measured by actigraphy over days of wear.
Time frame: Baseline, 13 weeks, 26 weeks
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for May 2028, 36 months after the start.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 36 months is above that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of British Columbia →